We analyzed the late outcomes of 429 long-term survivors post allogeneic hematopoietic SCT (allo-HSCT) who received transplant in our center between 1981 and 2002, and were free of their primary disease for X2 years after allo-HSCT. Late recurrent primary malignancy was found in 58 (13.5%) patients and was the primary cause of late death. A total of 37 (8.6%) patients died of nonrelapse causes at a median of 5.5 years (range, 2-15.6 years) post allo-HSCT. The major non-relapse causes of death were chronic GVHD (cGVHD), secondary malignancy and infection. The probabilities of OS and EFS were 85% (95% cumulative incidence (CI) (81-89%)) and 79% (95% CI (74-83%)) at 10 years, respectively. Long-term allo-HSCT survivors were evaluated for late complications (median follow-up, 8.6 years (range, 2.3-22.8 years)). cGVHD was diagnosed in 196 (53.1%) survivors. The endocrine and metabolic complications were hypogonadism in 134 (36.3%) patients, osteopenia/ osteoporosis in 90 (24.4%), dyslipidemia in 33 (8.9%), hypothyroidism in 28 (7.6%) and diabetes in 28 (7.6%). Hypertension was diagnosed in 79 (21.4%), renal impairment in 70 (19.0%), depression in 40 (10.8%) and sexual dysfunction in 33 (8.9%) survivors. We conclude that in patients who receive allo-HSCT as treatment for hematological malignancy and who are free of their original disease 2 years post transplant, mortality is low and the probability of durable remission is high. Lifelong surveillance is recommended.
Introduction
Allogeneic hematopoietic SCT (allo-HSCT) is currently an established treatment modality for a variety of hematological and non-hematological malignancies, and for some nonmalignant life-threatening diseases. [1] [2] [3] [4] The annual number of allo-HSCT procedures as well as the number of diseases for which allo-HSCT is considered appropriate, have expanded over the years. 5 Survival post allo-HSCT has also gradually improved with development of technological aspects in supportive care, enhanced histocompatibility testing, safer conditioning regimens, more effective GVHD prophylaxis and better management of opportunistic infections. As currently more patients survive the early post allo-HSCT period and remain free of their primary disease for several years, the potential long-term complications are more evident. For many allo-HSCT survivors, cure or control of the underlying disease is not accompanied by full restoration of physical and psychological health. [6] [7] [8] [9] [10] Most of the studies reported on long-term survivors are multi-center registrybased reviews. 8, [11] [12] [13] In our center, more than a thousand allotransplants have been performed over the last two decades, with a close follow-up of survivors annually or biannually. Our large single institution cohort gives us a unique opportunity for reviewing long-term outcomes.
To determine the late outcomes and long-term complications of survivors after allo-HSCT, we retrospectively studied the charts of 429 patients who were alive and free of their original disease for at least 2 years posttransplantation. We hereby report our results focusing on the medical problems seen in long-term survivors and stress the need of medical surveillance.
Patients and methods

Patient population
Between January 1981 and December 2002, a total of 894 patients underwent allo-HSCT for hematological malignancies at Leukemia/BMT Program of British Columbia in Vancouver, Canada. All patients provided a written informed consent. A total of 465 patients died or had relapsed within 2 years of transplantation and were excluded from this analysis. A total of 429 patients were alive and free of their primary disease for at least 2 years after transplantation and represented the population of this retrospective analysis. The Institutional Review Boards of the Vancouver General Hospital, and the University of British Columbia approved this retrospective analysis. The patients and transplant characteristics for the entire group are summarized in Table 1 .
Data collection
Most survivors were still being seen annually or bi-annually by their primary BMT physician. A total of 291 long-term survivors (79%) were seen regularly and had a date of last follow-up at our clinics o2 years before the data were pulled. A total of 78 patients (21%) had a date of last follow-up of 2-3 years, but communications, letters, study results and clinic notes were regularly received by their primary BMT physician from their primary oncologist/ hematologist or family physician. Pertinent information regarding patients is regularly prospectively entered in our program database (BMT Serve 3.1.4) whenever new information is available. Determination of remission status, cause of death and monitoring for the occurrence of late complications were performed by computer database search and by reviewing charts, clinic notes, medical correspondence, study results, death certificates and autopsy information, when available.
Statistical analysis and definitions
The date of allo-HSCT was considered day 0, and followup date was to the date of last medical examination. Survival analyses were done according to the method of Kaplan and Meier 14 and compared using the log-rank test. OS was calculated from the date of allo-HSCT to the date of death from any cause or until the date of last known follow-up. PFS was calculated from the date of allo-HSCT to the date of death or to the date of relapse of primary disease. Patients who died while in relapse were considered to have relapse-related death, even if this was not the recorded proximal cause of death. Similarly, patients who died with active chronic GVHD (cGVHD) were considered to have died of this complication even if other complications were recorded as the proximal cause of death. Infection was considered the cause of death among patients dying of infection without active cGVHD or relapse. Longterm survivors are patients who are still alive with or without relapse at last follow-up. Late complications are defined as complications occurring in long-term survivors. Clinical grading of cGVHD was based on Seattle criteria. 15 Arterial hypertension was defined as chronically elevated systolic blood pressure X140 mm Hg and/or a diastolic pressure X90 mm Hg. Dyslipidemia was defined as elevated fasting lipid profile above normal range, and renal impairment was considered when serum creatinine was persistently above the upper limit of normal. In men, hypogonadism was defined as serum testosterone levels below normal range with the need for testosterone replacement therapy. In women, hypogonadism was defined as premature onset of menopausal symptoms coupled with high leutinizing hormone and follicle stimulating hormone levels. Bone mineral density was measured by dual energy X-ray absorptiometry. Bone mineral density within À1 to À2.5 s.d. of mean young adult values defined osteopenia; whereas osteoporosis was present when bone mineral density values were greater than À2.5 s.d. below the mean young adult values.
The competing risk method was used to calculate the cumulative incidence (CI) of relapse, non-relapse mortality and secondary malignancy. The following were evaluated as potential prognostic factors for relapse and survival: age, sex, initial diagnosis, interval from diagnosis to HSCT, type and subtype of HSCT, donor-recipient sex, conditioning regimen, GVHD prophylaxis and cGVHD. Univariate and multivariate analyses were performed using a Cox proportional hazard technique. 16 
Results
A total of 429 allo-HSCT recipients were alive and free of their primary disease for at least 2 years after transplantation and represent the population of this retrospective analysis. A total of 60 patients have died of relapsed disease or nonrelapse causes. A total of 369 long-term survivors were evaluated for late complications ( Figure 1 ). The median duration of follow-up for long-term survivors was 8.6 years (range, 2.3-22.8 years). In total, 142 of the 369 patients (38.5%) were followed up for at least 5 years, 104 patients (28.2%) were followed up for at least 10 years and 40 patients (10.8%) were followed up for at least 15 years.
Relapse
Late recurrence of primary malignancy occurred in 58 patients (13.5%) at a median of 3.1 years (range, 2.0-12.8 years) after allo-HSCT. The 5-year, 10-year and 15-year CIs of relapse were 11% (95% CI (8-14%)), 14% (95% CI (11-18%)) and 18% (95% CI (13-23%)), respectively. The latest relapse was recorded 12.8 years post allo-HSCT. The overall CI of relapse is shown on Figure 2 . There was no statistically significant difference in CI of relapse by diagnosis (P ¼ 0. 
Survival and mortality
Of the 429 patients, 60 (14%) patients have died, 23 due to relapse and 37 due to non-relapse causes ( Figure 1 ). The overall CI of non-relapse mortality is shown on Figure 3 . There was no statistically significant difference in CI of non-relapse mortality by diagnosis (P ¼ 0.88). The nonrelapse causes of death were cGVHD (11 patients), secondary cancer (9 patients), infection (4 patients), coronary artery disease (CAD) (3 patients), miscellaneous (7 patients) and unknown (3 patients). The 5-year, 10-year and 15-year OS were 92% (95% CI (89-94%)), 85% (95% CI (81-89%)) and 79% (95% CI (72-84%)), respectively, and the 5-year, 10-year and 15-year PFS were 86% (95% CI (82-94%)), 79% (95% CI (74-83%)) and 70% (95% CI (63-76%)), respectively. At 15 years post allo-HSCT, nonrelapse mortality had a CI of 12% (95% CI (9-22%)) ( Figure 4 ).
Prognostic factors for relapse and survival
Univariate analysis using the entire cohort identified absence of cGVHD and non-TBI conditioning as predictors for relapse, but not OS. Relative risk (RR) for relapse was 0.46 with CI (0.26-0.77) for patients with Long-term survivors, evaluated for late complications (n=369) Figure 1 Flow of patients through the study. Out of 894 allogeneic hematopoietic SCT (allo-HSCT) recipients, 429 were alive and disease-free X2 years post transplant and they represented the study population. Of these 429 patients, 60 patients died either due to relapse or non-relapse causes. The other 369 were long-term survivors and they were evaluated for late complications. Figure 4 Overall and relapse-free survival for patients who were alive and free of their primary disease X2 years post allogeneic hematopoietic SCT (allo-HSCT) (429 patients). Clinical depression was a problem for 40 (10.8%) survivors, it resolved in 7 (17.5%), whereas 33 (82.5%) were still on antidepressants on the last follow-up. Two survivors attempted suicide. Cognitive impairment and other psychiatric disorders were found in 9 (2.4%) and 10 (2.7%) survivors, respectively; for some of them (three each), it resolved with time. Sexual dysfunction was reported in 33 (8.9%) survivors. Renal impairment was seen in 70 (19.0%) survivors. It resolved over time in 23 (32.8%) patients. On last follow-up, it was still a problem for 47 (67.1%) of those who had it initially. Dialysis was needed at some point in five patients.
Out of 306 evaluable patients, 260 (84.7%) were able to return to work/school, 18 (6.9%) as part timers and 242 (93.1%) as full timers. The other patients were unevaluable either because they did not work to start with or reached the age of retirement while on therapy.
Discussion
Patients who receive allo-HSCT are subjected to close follow-up in the first 2 years post transplantation. After this period, follow-up becomes less consistent and many of the late complications are missed or underestimated. Most of the studies reporting on long-term survivors are registrybased, including patients from a variety of centers with different approaches, 8, [11] [12] [13] some combining auto-and allo-HSCT recipients. 12, 13 Some of the studies addressed specific diseases 10, 17, 18 others addressed specific complications. 11, 13, 17, 19 In contrast, our study is based on large single institution experience with a consistent approach, including only allo-HSCT patients with different primary diagnoses who have extended 'in-house' follow-up allowing for detection of late death and complications. As with any retrospective study, this study has known weaknesses, including potential bias in capturing patients' complications.
This study of 429 patients who were disease-free for at least 2 years post transplantation shows that such patients have high durable remission rates, lower risks of relapse and late death, but definite late toxicity. Our results are remarkable for their consistency with other studies with respect to the main causes of late death post allo-HSCT. A report from The International Bone Marrow Transplant Registry on 679 deaths among 6691 patients who were free of their primary disease 2 years after transplantation showed that relapse was the primary cause of late death, followed by GVHD, infection and secondary cancer. 8 Most patients who relapsed post allo-HSCT in our series were treated aggressively, which resulted in half of them becoming long-term survivors with a median survival from relapse of 9.3 years. This may suggest that aggressive modes of therapy for some patients relapsing after HSCT should be considered. Of the 58 patients who had disease relapse X2 years post allo-HSCT, 14 patients had CML. All CML patients had morphological relapses documented by BM aspirate and biopsy. Cytogenetics and molecular studies were performed on BM samples at that time, but not routinely before relapse. A total of 5 of 14 patients received DLI and entered into CR2 with 1 of 5 had subsequent relapse and received Imatinib leading to CR3. A total of 7 of 14 had Imatinib single agent, of whom one had no response and died with disease progression and one received DLI in CR2 post Imatinib. One patient had IFN only and went into CR2, another patient received Hydroxyurea followed by Imatinib.
Secondary malignancy is a well documented long-term complication associated with allo-HSCT. 11, 19, [20] [21] [22] [23] [24] Radiation and chemotherapy used for treatment of primary disease and in conditioning regimens, as well as profound immunosuppression post allo-HSCT have been identified as contributing factors. 19, 20 In our cohort (429 patients), the CI rate of secondary malignancy was 4.3% at 17.6 years with a median time of 6.8 years post allo-HSCT (Figure 2 ). In our univariate and multivariate analyses, age group (o40 vs X40), conditioning regimen (TBI-based vs non-TBI-based), transplant type (related vs unrelated), primary diagnosis or chronic GVHD did not seem to play a role in increasing the risk for secondary malignancy in long-term survivors (Table 3) .
Chronic renal impairment post HSCT is multifactorial, although drugs are likely the main culprit. 25 Delayed renal failure post HSCT has been reported in pediatric and adult patients. This type of delayed nephropathy may be related to TBI enhanced by chemotherapy. 26, 27 In our univariate and multivariate analyses, we found that age X40 years was associated with an increased risk for renal impairment compared with age 14-39 years. RR was 3.81 CI (1.86-7.78) and 4.37 CI (2.08-9.19) in univariate and multivariate analyses, respectively, for patients X40 years compared with younger patients (P ¼ 0.0001 for both). TBI-based conditioning did not play a role as risk factor for chronic renal impairment, but primary diagnosis seemed as a risk factor for renal impairment (Table 3) .
Dyslipidemia and hypertension are well-known risk factors for CAD. It is unknown whether other factors, such as the cardiotoxic effects of radiation therapy, chemotherapy, immunosuppressive drugs, cGVHD and its treatment, or infectious agents, are contributing causes. A report from Mayo clinic on fatal CAD after unrelated donor HSCT documented donor hematopoietic cells having transformed into myocytes as a cause for triplevessel stenosis in one patient. 28 Aggressive treatment of known cardiac risk factors for CAD is recommended. A recent retrospective single-center cohort study showed that long-term survivors post allo-HSCT are at risk for cardiovascular disease, as compared with patients treated with autologous transplantation. 29 Baker et al. 30 have found that HSCT survivors have a higher risk of diabetes and hypertension, which potentially lead to higher cardiovascular events. In our univariate and multivariate analyses age group, conditioning therapy (TBI-based vs non-TBIbased), transplant type (related vs unrelated), primary diagnosis or chronic GVHD did not seem as risk factors for CAD (Table 3) .
Gonadal failure is the most frequent endocrine complication of high-dose chemotherapy and radiotherapy post allo-HSCT, and recovery is rare. 31 Ovarian failure is found in 95% of women and spermatogenesis damage was likely in 47% of men after alkylating agents. 31 In our cohort of long-term survivors, hypogonadism was seen in 68.8% of women. This discrepancy between reported loss of ovarian function (95%) and 68.8% on long-term follow-up (our data) may support the possibility that some of these patients may develop ovarian recovery, 32 or could merely be owing to lack of reporting.
In our study, 19 patients were infected with HCV between 1981 and 1992, when HCV testing was unavailable. Five of them have died and 14 patients are still alive. After a median follow-up of 15.5 years (range, 9.03-22.77 Table 3 Univariate and multivariate analyses of risk factors for major late complications in long-term survivors (369 patients) years), none of them developed signs or symptoms suggestive of liver cirrhosis. In a study from France, 96 patients who acquired HCV-infection during HSCT were followed up for a median of 15.7 years, 15 patients developed biopsy-proven liver cirrhosis. 33 The reported median time to cirrhosis in transplant recipients was 18 years compared with 40 years in HCV-infected patients without transplant. 33 Strasser et al. 34 found that cirrhosis after HSCT was mainly attributed to hepatitis C. In another study from the same group on long-term survivors, with over 10 years follow-up, HCV infection was not associated with excess mortality. 35 Most patients have adequate immune reconstitution by 1 year after transplant, but patients with cGVHD remain immunoincompetent and are at higher risk of infections. Two years and more post HSCT, Varicella zoster virus (VZV) infection was still an active issue occurring in 16.5% of long-term survivors. A study from the University of Minnesota reported an increased incidence of VZV reactivation until 10.8 years post BMT with the highest incidence within the first 18 months post BMT. 36 Koc et al. 37 reported an incidence of VZV reactivation of 59% among 47 patients who survived for X2 years post allo-HSCT. In view of the high risk for VZV reactivation, it seems reasonable to recommend that all VZV-seropositive patients and those with a history of VZV infection after allo-HSCT should receive prophylaxis with low-dose acyclovir or valacyclovir for at least 1 year if they are off-immunotherapy and as long as they are on immunosuppressive treatment for GVHD.
In conclusion, allo-HSCT is currently a well-established treatment modality offering the potential for cure to increasing numbers of patients. The majority of patients who survive disease-free for more than 2 years post allo-HSCT, will be cured and can resume normal life activity, but with a fair number of serious late complications. With extended follow-up, late relapse remains a concern even though it is not common. Late complications, such as cGVHD, infections, secondary malignancies, cardiac, endocrine, psychological, mood and musculoskeletal disorders, are frequently seen in long-term survivors. Predictors and risk factors for long-term complications, regular follow-up and reporting on late complication are vital to increase awareness of patients and physicians, and to develop screening programs and guidelines 38 for prevention, early detection, monitoring and treatment of these complications.
